Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer calcium chews

This article was originally published in The Tan Sheet

Executive Summary

Flintstones and One-A-Day Scooby Doo! Bone Building Calcium Chews, on shelves now, "provide as much calcium as two 6.5 oz. glasses of milk, plus vitamin D to help absorb calcium," Bayer says. Recommended for children ages four to 12, chocolate-flavored chews are available in 45-count containers, sell for about $8.99. Print ads are appearing in October publications, TV spots broke Sept. 4, Bayer notes. Packaging claims: "According to the American Academy of Pediatrics, calcium intake in childhood may be a critical factor in preventing osteoporosis later in life"...

You may also be interested in...



Neurology At The Forefront Of US FDA Complex Innovative Trial Design Pilot

Wave’s Duchenne muscular dystrophy drug and Lilly’s chronic pain R&D will test the agency’s CID meeting pilot program, while FDA issues draft guidance that highlights potential uses for complex innovative trial designs.

US FDA And Sponsors Resolve Disclosure Issues On Complex Trial Design Pilot Projects

Agency officials can now discuss the ideas that have been accepted, though not in great detail.

US FDA Requests Ranitidine Removal But Also Encourages Research For Stable Formulations

FDA requests immediate removal of ranitidine OTC and Rx drugs after third-party testing finds contaminant NDMA increases during storage, especially at higher temperatures. CDER Director Janet Woodcock asks firms to reformulate products to be stable as the ingredient remains approved.

Topics

UsernamePublicRestriction

Register

PS094606

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel